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RESEARCH ARTICLE Open Access
NMD and microRNA expression profiling of the
HPCX1 locus reveal MAGEC1 as a candidate
prostate cancer predisposition gene
Henna Mattila1, Martin Schindler1, Jarkko Isotalo1, Tarja Ikonen1, Mauno Vihinen2, Hannu Oja3, Teuvo LJ Tammela4,
Tiina Wahlfors1 and Johanna Schleutker1*
Abstract
Background: Several predisposition loci for hereditary prostate cancer (HPC) have been suggested, including
HPCX1 at Xq27-q28, but due to the complex structure of the region, the susceptibility gene has not yet been
identified.
Methods: In this study, nonsense-mediated mRNA decay (NMD) inhibition was used for the discovery of
truncating mutations. Six prostate cancer (PC) patients and their healthy brothers were selected from a group of
HPCX1-linked families. Expression analyses were done using Agilent 44 K oligoarrays, and selected genes were
screened for mutations by direct sequencing. In addition, microRNA expression levels in the lymphoblastic cells
were analyzed to trace variants that might alter miRNA expression and explain partly an inherited genetic
predisposion to PC.
Results: Seventeen genes were selected for resequencing based on the NMD array, but no truncating mutations
were found. The most interesting variant was MAGEC1 p.Met1?. An association was seen between the variant and
unselected PC (OR = 2.35, 95% CI = 1.10-5.02) and HPC (OR = 3.38, 95% CI = 1.10-10.40). miRNA analysis revealed
altogether 29 miRNAs with altered expression between the PC cases and controls. miRNA target analysis revealed
that 12 of them also had possible target sites in the MAGEC1 gene. These miRNAs were selected for validation
process including four miRNAs located in the X chromosome. The expressions of 14 miRNAs were validated in
families that contributed to the significant signal differences in Agilent arrays.
Conclusions: Further functional studies are needed to fully understand the possible contribution of these miRNAs
and MAGEC1 start codon variant to PC.
Background
Prostate cancer is the most common form of cancer
affecting men in the Western world. In Finland, there
were 4234 new cancer cases diagnosed in 2008, and the
incidence of prostate cancer (PC) was 82.9/100.000 [1].
In addition to age, a well-established risk factor for PC
is a family history of the disease. In a large Scandinavian
twin study [2], it was reported that approximately 40%
of the risk for PC can be explained by heritable compo-
nents. This proportion is the highest ever reported for a
common malignancy. Most of the genes that are
involved in the causation of hereditary cancers have
been identified by linkage analysis. Several linkage stu-
dies of hereditary prostate cancer (HPC) have been per-
formed and the results have implicated many risk loci
located on different chromosomes, which indicates a
great heterogeneity of this disease [3]. One of the loci
found by linkage analysis is HPCX1 (OMIM %300147),
which is located on chromosome Xq27-q28 [4]. This
locus has proven to be important in the Finnish popula-
tion [5] and the region around the best linkage marker
was found to be in strong linkage equilibrium [6]. How-
ever, the susceptibility gene has not yet been identified
because the chromosomal region has an extremely
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complex genomic structure with multiple gene duplica-
tions and inversions that have hampered conventional
gene cloning methods [7]. The SPANX genes and
LDOC1 at Xq27 have been considered to be the best
positional candidate genes for HPCX1, but no direct evi-
dence for causative mutations in any of the genes stu-
died have been detected [8,9].
Mutations, especially nonsense mutations, in tumor
suppressor genes (TSGs) are common in the develop-
ment and progression of cancer. They give rise to in-
frame premature translation termination codons within
the coding regions of genes and lead to truncated pro-
tein translation products. However, the identification of
TSGs by classical cancer genetics methods is difficult
and slow. In addition, RNA transcripts carrying non-
sense mutations are usually targeted for degradation
through nonsense-mediated decay (NMD) [10]. NMD is
a complex process in mammalian mRNA metabolism,
and its function is to eliminate faulty transcripts and
control the expression of normal genes.
A conventional strategy for the identification of dis-
ease genes is to use microarrays to compare the levels
of gene-specific mRNA expression between patient and
control samples. However, identification of the mutated
gene can be obscured by inter-individual variation and
secondary changes in gene expression caused by the dis-
ease process. Noensie and Dietz [11] reported an alter-
native strategy that circumvents these limitations, called
GINI (Gene Identification by NMD Inhibition), in which
the patient sample is compared to itself after the phar-
macological inhibition of NMD. Microarrays are then
used to identify potential nonsense transcripts that are
increased in abundance after the loss of NMD. Emetine
was used to block the pathway, but was problematic as
emetine induces a stress response that results in the
upregulation of additional transcripts. Ionov et al. [12]
combined the emetine treatment with actinomycin D,
which effectively prevents the upregulation of stress
response genes while still stabilizing mutant transcripts.
Inactivation of autosomal tumor suppressor genes is a
two-step process involving the mutation of the target
gene and the loss of the wild type allele. In lymphoblas-
toid cell lines established from patient samples, the nor-
mal wild type allele can mask the effect of a mutated
allele. However, because males have only one X chro-
mosome, there is only one allele of the X chromosomal
germline genes. Therefore, truncated tumor suppressor
mRNAs may be identified by using NMD method
applied for RNA extracted from patients’ lymphoblastoid
cell lines.
Cancer is fundamentally a disease of disordered gene
expression. Since no causative mutations have been
identified from the transcribed genes of the HPCX1
region, it is possible that the defect occurs at the
regulatory level. Regulatory defects might also explain
the relatively late onset of the disease, assuming a poly-
genic model for PC development with additive effect to
the phenotype. MicroRNAs (miRNAs) are small RNA
molecules that regulate gene expression post-transcrip-
tionally [13]. They play an important role in diverse bio-
logical processes and, accordingly, altered miRNA
expression is likely to contribute to human disease,
including cancer. It has been shown that miRNA pro-
files are surprisingly informative. They become altered
with the development and progression of PC [14] and
have a very important role in the biology of the disease
[15]. Since considerable amount of miRNAs are located
within intronic regions and regulated by the host gene
promoter [16], miRNA expression profiles give us one
possibility to study disease related variations in non-pro-
tein coding chromosomal areas and this could lead to
identification of regulatory variants especially in region
with complex genomic structure like one in chromo-
some X.
Here, we present a study with Finnish multiplex
HPCX1 linked families in which we have characterized
the HPCX1 locus by NMD and miRNA microarray
methods and evaluated the role of HPCX1 in the causa-
tion of familial prostate cancer.
Methods
Study population
NMD microarray analysis
Collection of the Finnish families with PC has been
reported previously [5]. Based on the first linkage to
HPCX1 in Finland [5], six affected and six healthy
males for controls were selected from the linked
families for NMD microarray analysis. Controls were
the oldest healthy brothers of the affected males. The
clinical characteristics of the patients are described in
Table 1.
miRNA microarray analysis
For the miRNA microarray analysis, the original number
of HPCX1-linked families was increased by seven based
on recent linkage analysis [17]. As in the NMD study,
the oldest possible healthy brother of the affected males
was chosen as the control. The clinical characteristics of
the patients are described in Table 1.
Association analysis
The P.Met1? variant was analyzed in the youngest
affected patient from 163 HPC families, 757 patients
with unselected PC, 757 healthy male blood donors, 764
healthy female blood donors, 375 men with benign pros-
tate hyperplasia (BPH), and 746 men who had a PSA
level of less than 1.0 ng/ml (PSA controls). Collection of
the Finnish families with PC has been reported pre-
viously [5]. In brief, families used in the association
study had two or more first- or second-degree affected
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relatives. The mean number of affected relatives was 2.8
(range 2-7) and the mean age at diagnosis for the pro-
bands was 63.0 years (range 43-86). The youngest
affected individual from each family was initially used in
the association analysis. The unselected cases included
consecutive patients diagnosed with PC in the Pirkan-
maa Hospital District from 1999-2001. The mean age at
diagnosis of the men with unselected PC was 69.0 years
(range 45-93). The men with BPH were also patients
from the Pirkanmaa Hospital District. The diagnosis of
BPH was based on lower urinary tract symptoms, free
uroflowmetry, and evidenced by palpation or transrectal
ultrasound of increased prostate size. If PSA was ele-
vated, then the patients underwent biopsies to exclude
PC. The indication for biopsy was a total PSA level of ≥
4 ng/ml or a total PSA level of 3.0-3.9 ng/ml with the
proportion of free PSA < 16%. The mean age of the
BPH patients was 73 years. The PSA controls were from
the Finnish population-based prostate cancer screening
trial [18]. The mean age of the men was 67.5 years
(range 64-74). The population controls consisted of
DNA samples from anonymous male and female blood
donors obtained from the Finnish Red Cross in
Tampere.
Permission to collect and use blood samples and clini-
cal data from prostate cancer patients was granted by
the Institutional Review Board of Tampere University
Hospital and City of Tampere. Written informed con-
sent for use of their samples as well as medical records
was obtained from all individuals participating in this
study.
Cell culture and drug treatments
In the NMD microarray experiment, the cell lines were
derived by Epstein-Barr virus transformation of periph-
eral mononuclear leukocytes from patients and their
healthy brothers. Lymphoblastoid cell lines were grown
in RPMI-1640 medium (Lonza, Walkersville, MD, USA)
supplemented with 10% fetal bovine serum (Sigma-
Aldrich, St. Louis, MO, USA) and antibiotics. The eme-
tine treatment protocol was described previously [12].
Briefly, for each cell line, we treated half of the subcon-
fluent cells with 100 μg/ml of emetine dihydrochloride
hydrate (Fluka, Buchs, Switzerland) and the rest were
used as untreated controls. Both the treated and
untreated cells were incubated for 10 h at 37°C. After
this, actinomycin D (Sigma-Aldrich) was added to the
treated and untreated cells, and they were incubated for
4 h at 37°C. Cell pellets were snap-frozen and total
RNA was extracted from treated and untreated cells
with Trizol according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA). In the miRNA micro-
array experiment, the lymphoblastoid cell lines were
grown similarly as above, but without drug treatments.
RNA yields were quantified using an ND-1000 spectro-
photometer (Nanodrop Technologies, Wilmington, DE,
USA).
Oligonucleotide array protocol
mRNA levels in the treated and untreated cells were
measured using the Agilent 44 K array according to the
manufacturer’s instructions (Agilent Technologies, Inc.,
Santa Clara, CA, USA). Twenty micrograms of total
Table 1 Demographic, clinical, and pathological characteristics of the patients in microarray analyses
Patient Diagnosis age Gleason score WHO grade T* N † M ‡ Primary PSA§
015-001** 53 y 7 m n.a. II T1c Nx M0 n.a.
043-001** 50 y 9 m 6 II T2 Nx M0 3.8
232-001** 70 y 7 m 7 II T1c Nx M0 6.2
232-002** 75 y 5 m n.a. n.a. T1a Nx M0 1.3
248-006** 59 y 3 m 6 I T1c Nx M0 2.9
311-003** 60 y 4 m 6 II T2 Nx M0 21.9
001-002 71 y 8 m n.a. II T3 Nx M0 n.a.
292-010 47 y 11 m 6 II T2 Nx Mx 5.2
408-002 67 y 5 m 7 II T1c Nx Mx 5.5
236-006 75 y 11 m n.a. n.a. T3 Nx Mx 85
402-003 67 y 3 m 6 I T2 Nx M0 13
402-001 67 y 11 m 7 II T1c Nx M0 15
413-003 55 y 3 m 7 II T1c Nx M0 6.4
362-001 50 y 7 m 6 I T1b Nx M0 6.9
362-002 49 y 4 m 6 I T1c Nx Mx 41.9
*The size of the tumor
†Regional lymph nodes
‡Distant metastases
§Prostate specific antigen
**Patients in the NMD array
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RNA were used to generate fluorescent Cy-3-labeled
cRNA (control cells) and Cy-5-labeled cRNA (treated
cells) using an Agilent Fluorescent Direct Label Kit.
Labeled RNAs were pooled and hybridized to the Agi-
lent 44 K Whole Human Genome Oligonucleotide
Microarrays (Agilent Technologies) containing over
33,000 known and novel human genes (~41,000 human
genes and transcripts). A total of 12 arrays were hybri-
dized, one for every individual. Microarray slides were
scanned (Agilent microarray scanner) after hybridiza-
tion, and data was extracted using Feature Extraction
software, version A.7.5.1. (Agilent Technologies). For
data analysis, the raw microarray expression values of
the rMeanSignal and gMeanSignal variables were first
background-adjusted and a natural logarithm of a ratio
of the variables rMeanSignal and gMeanSignal was
taken. The log-ratio values were normalized between
arrays by using the quantile normalization method. A
linear mixed model was then used as a method for iden-
tifying the set of differentially expressed genes in a con-
sidered experimental set-up. The normalized expression
values of each gene at Xq27-28 were separately modeled
by the linear mixed model that included the treatment
effect (i.e., the affected person versus healthy) as a fixed
effect and the family effect as a random effect. In the
model analysis, a considered gene was declared differen-
tially expressed if the calculated estimate for the para-
meter associated with the fixed treatment effect was
greater than zero, and if, at the same time, the p-value
in the t-test for the null hypothesis concerning the fixed
effect parameter being zero was smaller than the cut-off
value of 0.025. The oligonucleotide microarray data have
been deposited in NCBI’s Gene Expression Omnibus
http://www.ncbi.nlm.nih.gov/geo following the MIAME
guidelines and are accessible through GEO series acces-
sion number GSE24205.
Mutation screening and genotyping
Mutation screening of the coding regions of selected
genes and the genotyping of the P.Met1? mutation were
performed by sequencing. Genomic DNA was extracted
from peripheral blood samples using a commercially
available kit (Puregene, Gentra Systems, Minneapolis,
MN, USA). For sequencing analysis, PCR products were
purified in 96-format Acro Prep Filter Plates (Pall Life
Sciences, Ann Arbor, MI, USA) using the Perfect Vac
Manifold vacuum machine (Eppendorf AG, Hamburg,
Germany). Sequencing was performed according to the
manufacturer’s instructions using a BigDye Terminator
v.3.1 Cycle Sequencing Kit and an automated ABI
PRISM 3130xl Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). Sequence analysis was done with
Sequencher 4.2.2 software (Gene Codes Corporation,
Ann Arbor, MI, USA).
MicroRNA array protocol
MicroRNA expression levels in lymphoblastoid cell lines
were detected using an Agilent Human miRNA V2
Oligo Microarray Kit (Agilent Technologies). First, 100
ng of total RNA was used as a starting material, and
miRNAs were labeled using the Agilent miRNA Label-
ing Kit. Labeled RNA was hybridized to Agilent miRNA
arrays with eight identical arrays per slide, with each
array containing probes directed against 723 human and
76 human viral miRNAs. Slides were scanned (Agilent
microarray scanner) after hybridization and data was
extracted using Feature Extraction software, version
9.5.1. (Agilent Technologies). For data analysis, low
quality samples and non-expressed miRNAs were first
removed ending up with 29 individuals from 9 families
and with 333 miRNAs. Inside every family the direc-
tional distance of healthy individuals from patients was
calculated. The distance used here was based on Ken-
dal’s tau (distance = (1-tau)/2) and the distance between
clusters was computed using Ward’s method. By decom-
posing Kendal’s tau into each miRNA’s contribution the
distance induced by every miRNA can be quantified
separately. The direction of this distance inside every
family is marked positive if the average rank miRNA
expression for patients is higher than for healthy indivi-
duals and negative if the average rank miRNA expres-
sion for healthy individuals is higher than for patients.
The overall directional distance for every miRNA is
obtained by summing up these directional distances
over all families. Then the permutation p-value was
computed by permuting healthy individuals and patients
randomly inside every family, computing the overall
directional distance, repeating this many times and the
final permutation p-value is the proportion of these per-
muted distances higher or lower than the original dis-
tance. The micro-RNA microarray data have been
deposited in NCBI’s Gene Expression Omnibus http://
www.ncbi.nlm.nih.gov/geo following the MIAME guide-
lines and are accessible through GEO series accession
number GSE24205.
MicroRNA target detection
The miRanda algorithm [19] was used for finding geno-
mic targets for miRNAs. For each miRNA, target genes
were selected on the basis of three properties: sequence
complementarity using a position-weighted local align-
ment algorithm, free energies of RNA-RNA duplexes,
and conservation of target sites in related genomes. All
of the human miRNA sequences were downloaded from
the Sanger Institute miRBase [20], and they were aligned
with the genomic sequences of variant sites from the
sequenced genes. The aim was to identify miRNA target
sites that either appear or disappear due to variants.
Based on the total score value given to every wild type
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and mutant sequence combination by the miRanda algo-
rithm, the difference between values was calculated. The
top 5% of the highest differences were selected for
further analysis.
miRNA expression validation
Expression of miRNAs in the lymphoblastoid cell lines
was validated by the specific TaqMan MicroRNA assays
according to the manufacturer’s instructions (Applied
Biosystems). TaqMan microRNA assays were performed
using Bio-Rad Laboratories’ CFX384 real-time PCR
detection system with the Bio-Rad C1000 thermal cycler
(Bio-Rad Laboratories, Inc., US).
Statistical analyses
Distribution of the genotypes and alleles, the odds ratio
(OR), and the 95% confidence interval (CI) were calcu-
lated with the SPSS statistical software package, version
15.0 (SPSS, Chicago, IL). Associations with demo-
graphic, clinical, or pathological features of the disease
(age at diagnosis, PSA value at diagnosis, T-stage, WHO
grade, and Gleason score) were tested among unselected
PC and HPC cases using R software http://www.r-pro-
ject.org.
Results
In order to identify genes containing inactivating muta-
tions in the Xq27-q28 region, an NMD microarray ana-
lysis with Agilent 44 K Whole Human Genome
oligonucleotide microarrays was performed in the
families showing the strongest linkage to HPCX1. The
candidate genes (n = 17) for subsequent sequence analy-
sis were selected according to the microarray analysis
(RBMX, CSAG2, RAP2C, SOX3, MBNL3, ZNF75,
MAGEC1, MAGEA1, MAGEA11, MAGEC3, MAGED1,
U66046, SSR4, VBP1, LDOC1, TKTL1, CD40LG) (Table
2). All identified stress response genes were excluded
[21]. No truncating mutations were detected, but a total
of 34 changes were found by direct sequencing. Eight of
the changes were missense variants, six were silent
changes, and twenty of the variants took place in
introns, 5’UTR, or 3’UTR regions. Twenty of the
changes were novel and not found in any genomic data-
bases. A summary of the identified variants is presented
in Table 3.
The most interesting variation selected for follow-up
was the MAGEC1 p.Met1? (c.2T > C; Met > Thr) start
codon mutation found in family 311. The frequency of
that mutation was determined by sequencing among
patients with unselected PC or HPC and in the control
groups. The carrier frequencies for p.Met1? were 2.45%,
1.72%, 0.92%, 0.53%, 1.21%, and 0.65% in the probands
with HPC, unselected PC cases, male population con-
trols, BPH controls, PSA controls, and female popula-
tion controls, respectively. The frequency of P.Met1?
was found to be in Hardy-Weinberg equilibrium in con-
trols. A statistically significant difference was observed
in the carrier frequencies of the P.Met1? variant
between the sample groups, and an association was seen
between the variant and unselected PC and HPC (see
Table 4). The association was strongest when male and
female blood donors and BPH patients were used as a
control group (OR = 2.35, 95% CI = 1.10-5.02 for unse-
lected PC; OR = 3.38, 95% CI = 1.10-10.40 for HPC).
The association between the frequency of the variant
and the disease phenotype, including tumor WHO
Table 2 Genes selected for resequencing based on NMD oligoarray analysis
Gene ID Gene name Cytogenetic band Genomic location (strand) Selection criteria
RBMX RNA binding motif protein, X-linked Xq26.3 135 951 351-135 962 939 bp (-) p < 0.05
CSAG2 Homo sapiens CSAG family, member 2 Xq28 151 922 445-151 928 738 bp (+) p < 0.05
RAP2C Homo sapiens RAP2C, member of RAS Xq25 131 337 053-131 353 471 bp (-) p < 0.05, fold change > 1.5
SOX3 SRY (sex determining region Y)-box 3 Xq27.1 139 585 152-139 587 225 bp (-) p < 0.05
MBNL3 Muscleblind-like 3, (Drosophila) Xq26.2 131 506 029-131 623 996 bp (-) p < 0.05
ZNF75 Zinc finger protein 75 Xq26.3 134 382 867-134 478 012 bp (-) p < 0.05
MAGEC1 Melanoma antigen family C, 1 Xq26 140 991 680-140 997 183 bp (+) p < 0.05
MAGEA1 Melanoma antigen family A, 1 Xq28 152 481 522-152 486 116 bp (-) p < 0.05, fold change > 1.5
MAGEA11 Melanoma antigen family A, 11 Xq28 148 769 894-148,798,928 bp (+) location
MAGEC3 Melanoma antigen family C, 3 Xq27.2 140 926 102-140 985 618 bp (+) location
MAGED1 Melanoma antigen family D, 1 Xp11.23 51 546 103-51 645 453 bp (+) p < 0.05
U66046 hypothetical protein FLJ44451 Xq28 148 615 451-148 616 127 bp (-) p < 0.05
SSR4 signal sequence receptor, delta Xq28 153 058 971-153 063 960 bp (+) p < 0.05
VBP1 von Hippel-Lindau binding protein 1 Xq28 154 444 550-154 468 098 bp (+) p < 0.05
LDOC1 leucine zipper, down-regulated in cancer, 1 Xq27 140 269 930-140 271 310 bp (-) p < 0.05
TKTL1 transketolase-like 1 Xq28 153 524 024-153 558 700 bp (+) p < 0.05
CD40LG CD40 ligand Xq26 135 730 336-135 742 549 bp (+) p < 0.05
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grade, Gleason score, T-stage, age at diagnosis, and PSA
value at diagnosis, was also analyzed among the unse-
lected PC cases as no complete data were available for
the HPC cases. No significant associations were found
from these studies (data not shown). Additional samples
from three prostate cancer families carrying the p.Met1?
variant were also analyzed, but cosegregation of the p.
Met1? was incomplete (data not shown) which is quite
expected for a low penetrance gene.
MicroRNA expression levels in lymphoblastoid cell
lines were determined with Agilent Human miRNA
arrays. The most differentially expressed miRNAs when
testing against both alternatives (miRNA expression is
either up- or downregulated in case vs. controls) are
presented in Table 5 and 6 together with information
about genomic and intronic/intergenic location. The
miRanda algorithm produced 1211 different variant-
miRNA combinations with a total score value above the
cut-off value. From the 29 differentially expressed miR-
NAs between patients and healthy individuals twelve
miRNAs for validation were selected based on that they
supposedly had a target site in MAGEC1 gene (Table 5
and 6). In addition, miRNAs located in X chromosome
were selected for validation. Validation of these selected
miRNA expressions in cell lines was based on specific
TaqMan MicroRNA Assays (Tables 5 and 6, Figures 1,
2 and 3).
Discussion
The recognition that PC clusters within families has led
to the collection of HPC families with the goal of loca-
lizing and identifying PC susceptibility genes. Initially,
the PC susceptibility locus, HPCX1, was mapped to the
X chromosome by using a set of high-risk PC families
from the United States, Finland, and Sweden. The effect
of HPCX1 was proven to be the most important in the
Finnish population, where a specific haplotype in the
region was also identified [5,6]. Further, X-chromosomal
inheritance coheres with the results of our segregation
analysis of multifactorial recessive inheritance as the
only model in the Finnish population [22]. In this study,
a recently developed NMD microarray technology was
utilized for the analysis of the HPCX1 region with
brother pairs from HPCX1 linked families. Use of the
unaffected brothers as controls might be problematic
given the late age of prostate cancer diagnosis, but the
unaffected brothers were chosen to be the oldest possi-
ble from every family with no history of PC. Previously,
the manipulation of NMD together with expression
array analysis has proven to be a powerful tool for
Table 3 Summary of variants found in the HPCX1 region
from Finnish HPC families
Gene Variation* Amino acid change dbSNP
CD40LG c.148T > C p.Leu50Ser rs1126535
LDOC1 c.-62C > G - -
MAGEA1 c.-2924G > T - -
c.-264, G > A - -
c.813C > T p.Leu271 rs2233045
c.*17A > G - -
c.*477C > T - -
MAGEA11 c.96+38A > G - -
c.193-64T > C - -
c.266+10C > T - -
c.1077 C > T p.Leu359 -
c.*234T > C - -
MAGEC1 c.-2051G > A - -
c.-2008T > C - rs1003682
c.2T > C P.Met1? -
c.5-44T > C - -
c.74G > A p.Cys25Tyr rs176036
c.452C > T p.Thr151Ile rs176037
c.1327C > G p.Leu443Val rs62611966
c.1401C > G p.His467Gln rs176048
c.2125C > T p.His709Tyr rs56256227
c.3174G > A p.Glu1058 rs12845617
c.*53C > T - rs41300301
MAGEC3 c.-189C > T - -
c.259-66G > A - -
c.259-15T > C - -
c.880C > G p.Leu294Val -
c.958C > T p.Leu320 rs176025
MBNL3 c.923-11G > A - -
RBMX c.-1C > A - rs2011584
SUHW3 c.1851A > C p.Gly617 rs209238
c.2161+4C > T - -
c.2162-41T > C - -
ZNF75 c.1434 G > A p.Thr478 rs1129093
*Numbering is according to the cDNA starting at the A in the start codon.
Table 4 Association of the MAGEC1 P.Met1? variant with
unselected PC or HPC
Sample group Carrier
frequency
OR (95% CI) P
Male population controls 7/757 (0.92%) 1.00
Female population
controls
5/764 (0.65%) 1.00
Patients with BPH 2/375 (0.53%) 1.00
PSA controls 9/746 (1.21%) 1.00
Patients with unselected
PC
13/757 (1.72%) 1.99 (1.00-3.95)* 0.04*
2.35 (1.10-5.02)** 0.02**
Patients with HPC 4/163 (2.45%) 2.86 (0.98-8.38)* 0.04*
3.38 (1.10-10.40)
**
0.02**
*Male and female blood donors, BPH patients, and PSA controls used as a
control group.
**Male and female blood donors and BPH patients used as a control group.
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detecting novel gene mutations in cancer cells. Huusko
et al. [23] successfully identified EPHB2 gene mutations
in PC. Since then, mutations in melanoma cell lines
[24], colon cancer cell lines [25], and PC cell lines [26]
have been identified by inhibition of NMD.
Sequencing of 17 genes from the HPCX1 region did
not reveal any truncating nonsense mutations. The most
interesting variation for follow-up was in the start
codon (p.Met1?) of the MAGEC1 gene. An association
was later seen between the p.Met1? variant and
Table 5 Differentially expressed miRNAs between patients and healthy individuals: Testing against alternative that a
miRNA is upregulated in patients
Mature
miRNA1
p-
value
Pre-miR miRBase
ID
Location Possible target site in
MAGEC1
Validation (TaqMan)
hsa-miR-296-5p 0.0049 MI0000747 chr 20: intronic (AL136532)
hsa-miR-766 0.0157 MI0003836 chr X: intronic (SEPT6) + (in families 1,15,232,362)
hsa-miR-767-
3p
0.0189 MI0003763 chr X: intronic (GABRA3) + (in families
1, 15)
hsa-miR-151-
5p
0.0312 MI0000809 chr 8: intronic (PTK2) c.5-44T > C
c.*53C > T
+ (in family 1)
hsa-miR-133a 0.0316 133a-1:
MI0000450
chr 18: intronic (MIB1) c.74G > A + (in family 15)
133a-2:
MI0000451
chr 20: intronic
(C20orf166)
hsa-miR-451 0.0319 MI0001729 chr 17: intergenic c.1327C > G + (in family 1)
hsa-miR-23b 0.0393 MI0000439 chr 9: intronic (C9orf3) c.452C > T
c.1327C > G
+ (in families 1, 15, 413)
hsa-miR-223 0.0404 MI0000300 chr X: intergenic + (in families 1, 15, 362, 413)
hsa-miR-146a* 0.0404 MI0000477 chr 5: intergenic
hsa-miR-342-
5p
0.0410 MI0000805 chr 14: intronic (EVL) c.452C > T + (in families 248, 292, 402, 408,
413)
hsa-miR-183* 0.0433 MI0000273 chr 7: intergenic
hsa-miR-151-
3p
0.0438 MI0000809 chr 8: intronic (PTK2) c.5-44T > C
c.*53C > T
+ (in families 1, 402)
hsa-miR-129-3p 0.0465 MI0000473 chr 11: intergenic
hsa-miR-129* 0.0477 MI0000252 chr 7: intergenic
1miRNAs selected for validation are represented in bold
Table 6 Differentially expressed miRNAs between patients and healthy individuals: Testing against alternative that a
miRNA is downregulated in patients
Mature miRNA1 p-value Pre-miR miRBase ID Location Possible target site in MAGEC1 Validation (TaqMan)
hsa-miR-32 0.0001 MI0000090 chr 9: intronic (C9orf5) c.*53C > T + (in families 1, 248)
hsa-miR-30a 0.0102 MI0000088 chr 6: intronic (C6orf155)
hsa-miR-33a 0.0184 MI0000091 chr 22: intronic (SREBF2)
hsa-miR-345 0.0210 MI0000825 chr 14: intergenic
hsa-miR-195 0.0245 MI0000489 chr 17: intronic (AC027763) c.*53C > T + (in families 292, 362, 408)
hsa-miR-487b 0.0279 MI0003530 chr 14: intergenic c.*53C > T + (in families 248, 292)
hsa-miR-370 0.0292 MI0000778 chr 14: intergenic
hsa-miR-770-5p 0.0305 MI0005118 chr 14: intronic (MEG3) c.3174G > A -
hsa-miR-29c 0.0330 MI0000735 chr 1: intergenic c.1327C > G
c.2125C > T
+ (in families 1, 248, 362)
hsa-miR-34c-3p 0.0351 MI0000743 chr 11: intergenic
hsa-miR-148a 0.0426 MI0000253 chr 7: intergenic
hsa-miR-20b 0.0431 MI0001519 chr X: intergenic + (in family 1)
hsa-miR-29b 0.0478 29b-1: MI0000105 chr 7: intronic (AC016831)
29b-2: MI0000107 chr 1: intergenic
hsa-miR-212 0.0482 MI0000288 chr 17: intergenic c.3174G > A -
hsa-miR-7 0.0490 7-1: MI0000263 chr 9: intronic (HNRNPK)
7-2: MI0000264 chr 15: intergenic
7-3: MI0000265 chr 19: intronic (C19orf30)
1miRNAs selected for validation are represented in bold
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unselected PC and HPC. Interestingly, the association
was strongest when “supernormal” PSA controls were
excluded from the control group. The PSA controls
consisted of men with PSA levels < 1.0 ng/ml and a
mean age of 67.5 years, which is lower than the mean
age of BPH patients (73 years). As HPCX1 is suggested
to be a late-onset disease in the Finnish population [5],
as well as in some other populations [27], it is possible
that the younger PSA control group is actually more
saturated with the p.Met1? individuals who are at risk of
developing late-onset HPCX. MAGEC1 is a member of
the melanoma antigen gene (MAGE) family [28]. The
proteins of this family are tumor-specific antigens that
can be recognized by autologous cytolytic T lympho-
cytes. MAGEC1 is composed of four exons and encodes
a protein of 1142 amino acids. It is approximately 800
residues longer than other MAGE proteins due to the
insertion of a large number of short repetitive sequences
in front of the MAGE-homologous sequence. MAGEC1
is expressed in a significant proportion of tumors of var-
ious histological types, but is silent in normal tissues,
excluding the testis. Alternative start codons, mainly
GTG and TTG, are used in prokaryotes and, very rarely,
in higher organisms. One example is the vitamin-D
receptor (VDR) gene start codon polymorphism, where
a T/C polymorphism in the first of the two potential
start (ATG) codons results in two alleles that can be
distinguished by RFLP using the endonuclease FokI [29].
The biological function of the identified MAGEC1 start
codon variant in this case is difficult to assess since we
were not able to investigate the expression of MAGEC1
in individuals carrying the mutated allele in the absence
of other tissue material. Considering the conserved
structure and similar functions of MAGE proteins, it
might be possible that other members of the gene family
can partly compensate for the functions of MAGEC1 if
the start codon mutation totally blocks the translation
of the gene.
In this NMD array analysis, the false positive rate was
evidently high since no truncating mutations were found.
Emetine treatment followed by actinomycin D treatment
was used, but it has been observed that treatment with
Figure 1 Validation of miRNA expressions in families 1 and 15. In the upper row the normalized expressions of sixteen miRNAs are
presented (black bars indicate cancer patients and white bars indicate healthy brothers). In the lower row the corresponding expression values
measured with specific TaqMan miRNA assays are displayed.
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actinomycin D after emetine incubation does not have a
significant effect on treated cells, suggesting that the
combination of the drugs is not the best possible method
for this type of study [30]. A novel improvement to the
NMD protocol includes a combination of emetine and
caffeine treatment [25], which leads to a more efficient
identification of false positives produced by cell stress.
On the other hand, we might have missed genes that
actually carry truncating mutations. If the genes were
mutated both in the seemingly healthy males with a nor-
mal clinical phenotype and their already affected siblings,
they would have had the same profile as the stress
response genes and would have, therefore, been excluded.
In addition, relevant variants might have been missed by
being limited to use lymphoblastoid cell lines, as they
may not resemble the whole set of active genes in pros-
tate tissue. Although there is substantial amount of
evidence that lymphoblastoid cells encompasses a variety
of metabolic pathways that are specific to individuals
where the cells originated, making these cell lines suitable
for molecular and functional studies [31].
Despite its association with PC, the segregation of the
P.Met1? variant in studied families was incomplete. This
finding can also reflect the high phenocopy rate of the
disease, and as a consequence, even the most extreme
families may have a few sporadic cases. Currently, there
are no clinical or molecular tools to distinguish “true”
HPC cases from sporadic ones. Therefore, the incom-
plete segregation does not necessarily diminish the
importance of p.Met1? as a HPCX1 risk variant.
The number of publications reporting differential
miRNA expression in prostate cancer is constantly grow-
ing. Analyses have been performed for example in clinical
prostate specimens [32], and in PC cell lines, xenografts,
BPH vs. PC samples [33]. Most recently, miRNA expres-
sion profiles of androgen-responsive and castrate-resis-
tant PC cell lines were compared [34]. In all of these
studies, a set of 20-30 miRNAs unequivocally differen-
tiated the PC samples from the normal samples and non-
malignant precursor lesions, and specific miRNAs includ-
ing miR-125b, miR-145, and let-7c were repeatedly
detected differentially expressed in different studies.
In the current study, we hypothesized that miRNA
profiling could be used as a tool for discovering var-
iants from non-protein coding regions which could
explain the “dark” inheritance behind HPCX. Altered
miRNA expression in patients lymphoblastoid cells
could lead to the identification of germline variants in
promoter or other regulatory regions of protein coding
genes since considerable amount of miRNA expression
is correlated to host and target gene expression [35].
Possible explanation of differences in miRNA levels
could be their role in tumor development and initia-
tion. Already, several studies have shown that miRNAs
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Figure 2 Pedigree of HPCX1 linked family 1. Black square
denotes persons with prostate cancer, black square and circle with
white surroundings signifies patient with another type of cancer.
Age at diagnosis for prostate cancer patients (in years) is indicated
below the symbol. The pedigrees have been altered to protect
anonymity.
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in serum can be considered as biomarkers [36,37] and
serum miRNAs are mainly derived from circular blood
cells [38], the same way as lymphoblastoid cells. We
were able to identify 29 significantly differently
expressed miRNAs between patients and their healthy
brothers. Validation of the expressions of the selected
16 miRNAs with TaqMan assays were successful in
14/16 cases, including all four miRNAs located in the
X chromosome.
Conclusions
In conclusion, we suggest a role for MAGEC1 in genetic
PC susceptibility, especially in the HPCX1-linked form
of the disease. The start codon missense variation in the
MAGEC1 gene showed a borderline association between
the variant and both HPC and unselected PC, and there-
fore additional research is warranted. In addition, the
role of certain miRNAs needs further study, especially
since MAGEC1 was predicted to be one of their targets.
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